Inhibition of oxidative stress in atrial fibrillation
Disclosed herein are pharmaceutical compositions and methods for inhibiting oxidative stress in a subject having atrial or ventricular arrhythmias, ventricular failure or heart failure. The methods include administering an effective amount of a NOX2 inhibitor agent to the subject, wherein said administering is under conditions such that a level of oxidative stress in myocardial tissue is reduced or eliminated. The pharmaceutical compositions include a NOX2 inhibitor agent.
1. A method of inhibiting oxidative stress in a subject having atrial fibrillation (AF), comprising administering directly in atrial myocardial tissue of the subject having atrial fibrillation (AF) an effective amount of a NADPH oxidase 2 (NOX2) inhibitor agent, wherein the NOX2 inhibitor agent comprises a NOX2 shRNA and wherein said administering is under conditions such that a level of oxidative stress in atrial myocardial tissue of the subject is reduced or eliminated.
2. The method of claim 1 , wherein the NOX2 shRNA is SEQ ID NO: 1.
3. The method of claim 1 , wherein administering directly in atrial myocardial tissue of the subject having atrial fibrillation (AF) an effective amount of a NADPH oxidase 2 (NOX2) inhibitor agent comprises:
(a) providing an isolated therapeutic DNA comprising an small hairpin RNA (shRNA) against NOX2 mRNA (NOX2 shRNA) expression vector that encodes and expresses NOX2 shRNA in vivo; and
(b) administering directly the isolated therapeutic DNA in atrial myocardial tissue of the subject.
4. The method of claim 3 , wherein administering directly the isolated therapeutic DNA in atrial myocardial tissue of the subject comprises injecting the isolated therapeutic DNA.
5. The method of claim 1 , further comprising assessing a parameter of atrial tissue status in the subject.
6. The method of claim 5 , wherein assessing a parameter of atrial tissue status in the subject comprises monitoring an electrophysiological measurement associated with atrial fibrillation (AF) or assessing fibrosis status for a region of the myocardial tissue after administering NOX2 inhibitor agent to the subject.
7. The method of claim 5 , wherein assessing a parameter of atrial tissue status in the subject comprises monitoring an electrophysiological measurement associated with atrial fibrillation (AF) selected from AF onset, AF duration, conductivity and conductive inhomogeneity index.
8. The method of claim 3 , further comprising assessing an atrial fibrillation (AF) characteristic following administering directly the isolated therapeutic DNA.
9. The method of claim 8 , wherein the atrial fibrillation (AF) characteristic comprises at least one member selected from the group consisting of AF duration, AF episode inducibility, effective refractory periods and conduction inhomogeneity index.
10. The method of claim 1 , further comprising assessing at least one member selected from the group consisting of NOX2 nucleic acid, NOX2 polypeptide, superoxide production and fibrosis.
11. A method of treating a subject having atrial fibrillation (AF), comprising administering directly in atrial myocardial tissue of the subject having atrial fibrillation (AF) an effective amount of a NADPH oxidase 2 (NOX2) inhibitor agent, wherein the NOX2 inhibitor agent comprises a NOX2 shRNA and wherein said administering is under conditions such that a level of atrial fibrillation (AF) is reduced or eliminated.
12. The method of claim 11 , wherein administering directly in atrial myocardial tissue of the subject having atrial fibrillation (AF) an effective amount of a NADPH oxidase 2 (NOX2) inhibitor agent to the subject comprises:
(a) providing an isolated therapeutic nucleic acid comprising a small hairpin RNA against NOX2 mRNA (NOX2 shRNA) in vivo; and
(b) administering directly in atrial myocardial tissue of the subject having atrial fibrillation (AF) the isolated therapeutic nucleic acid.
13. The method of claim 12 , further comprising: (c) assessing atrial fibrillation (AF) status for the atrial myocardial tissue after administration of the therapeutic nucleic acid.
14. The method of claim 13 , wherein the atrial fibrillation (AF) status comprises at least one member selected from the group consisting of AF duration, AF episode inducibility, effective refractory periods and conduction inhomogeneity index.
15. The method of claim 11 , further comprising assessing at least one member selected from the group consisting of NOX2 nucleic acid, NOX2 polypeptide, superoxide production and fibrosis.
16. The method of claim 12 , wherein the isolated therapeutic nucleic acid is expressed from an expression vector encoding a NOX2 shRNA.